Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17694175 | 0.80 | ALDH1A1 (0.42) | MAPTLMNAUSP2ALDH1A1ALOX15 | |
| SCHEMBL14535851 | 0.80 | TSHR (0.33) | MAPTBRD4EGFR | |
| SCHEMBL9836735 | 0.80 | TSHR (0.33) | MAPTBRD4EGFR | |
| SCHEMBL10837418 | 0.78 | USP2 (0.38) | MAPTLMNAMAPK1EPHX2BRD4 | |
| SCHEMBL25497628 | 0.75 | SLC6A12 (0.35) | — | |
| SCHEMBL8444550 | 0.74 | EPHX2 (0.44) | EPHX2BRD4EGFR | |
| SCHEMBL4260159 | 0.71 | MAPT (0.38) | MAPT | |
| SCHEMBL17696579 | 0.71 | ALDH1A1 (0.40) | MAPTLMNAEPHX2USP2ALDH1A1 | |
| SCHEMBL1691605 | 0.70 | USP2 (0.46) | MAPTLMNAEPHX2BRD4EGFR | |
| SCHEMBL13359529 | 0.70 | USP2 (0.46) | MAPTLMNAEPHX2BRD4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054376-A1 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | PHARMOS CORPORATION | 2009-02-26 | — | — | US | disclosed |
| EP-1885709-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | Pharmos Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006129318-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | PHARMOS CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054376-A1 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | CNR2, CNR1, TRPV1 | MAPT 1506/4885LMNA 4360/4885MAPK1 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.